ISPOR - Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer In Spain- Management in the Later Lines of Therapy

Full Text

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer In Spain- Management in the Later Lines of Therapy

Abstract

Authors

U. Majethia G. Tremblay I. Kontoudis J. DeRosendo

Back to Volume 18, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now